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Molecular mechanisms of prion pathogenesis
Abstract
Prion diseases are infectious neurodegenerative diseases occurring in humans and animals with an
invariably lethal outcome. One fundamental mechanistic event in prion diseases is the aggregation of
aberrantly folded prion protein into large amyloid plaques and fibrous structures associated with
neurodegeneration. The cellular prion protein (PrPC) is absolutely required for disease development,
and prion knockout mice are not susceptible to prion disease. Prions accumulate not only in the central
nervous system but also in lymphoid organs, as shown for new variant and sporadic Creutzfeldt-Jakob
patients and for some animals. To date it is largely accepted that prions consist primarily of PrPSc, a
misfolded and aggregated beta-sheet-rich isoform of PrPC. However, PrPSc may or may not be
completely congruent with the infectious moiety. Here, we discuss the molecular mechanisms leading to
neurodegeneration, the role of the immune system in prion pathogenesis, and the existence of prion
strains that appear to have different tropisms and biochemical characteristics.
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Abstract
Prion diseases are infectious neurodegenerative diseases occurring
in humans and animals with an invariably lethal outcome. One fun-
damental mechanistic event in prion diseases is the aggregation of
aberrantly folded prion protein into large amyloid plaques and ﬁ-
brous structures associated with neurodegeneration. The cellular
prion protein (PrPC) is absolutely required for disease development,
and prion knockout mice are not susceptible to prion disease. Pri-
ons accumulate not only in the central nervous system but also in
lymphoid organs, as shown for new variant and sporadic Creutzfeldt-
Jakob patients and for some animals. To date it is largely accepted
that prions consist primarily of PrPSc, a misfolded and aggregated
β-sheet-rich isoform of PrPC. However, PrPSc may or may not be
completely congruent with the infectious moiety. Here, we discuss
the molecular mechanisms leading to neurodegeneration, the role
of the immune system in prion pathogenesis, and the existence of
prion strains that appear to have different tropisms and biochemical
characteristics.
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INTRODUCTION
Prion Diseases: A Medical
and Economic Crisis
Transmissible spongiform encephalopathies
(TSEs), or prion diseases, are neurodegenera-
tive diseases with an inexorably fatal outcome
for the affected host. As of today, no therapy
other than palliation is available. Prion
diseases have been responsible for entire cen-
turies of tragic episodes: From the end of the
nineteenth to the middle of the twentieth cen-
tury, ritualistic anthropophagy of central ner-
vous system (CNS)-derived tissues in Papua
New Guinea tribes led to kuru, which became
the prime cause of death in some tribes (1). In
the last quarter of the twentieth century, iatro-
genic transmission of prion-contaminated go-
nadotropins into humans caused ≥250 victims
of Creutzfeldt-Jakob disease (CJD). In the
past 20 years, more than 280,000 cattle suffer-
ing from bovine spongiform encephalopathy
(BSE) (Figure 1a) provoked a worldwide, ma-
jor food crisis with so far incomparable eco-
nomic consequences for the European Union
and other countries (2). In addition, trans-
mission of BSE to humans is believed to have
caused ≥200 cases of variant of Creutzfeldt-
Jakob disease (vCJD) (Figure 1b) (3, 4, 5).
The fact that most likely millions of people
have been in contact with BSE-contaminated
meat initiated a widespread health scare.
The good news is that the BSE crisis has
been largely resolved: Few cows succumb to
this disease annually, at least in those countries
that have implemented effective epidemiolog-
ical screening systems. Furthermore, the inci-
dence of vCJD, which for a while was feared to
rise to pandemic proportions, has not shown
a signiﬁcant rise in the number of total cases
(Figure 1b). Today the number of vCJD cases
is slightly higher in all non–United Kingdom
countries than in the United Kingdom itself.
Despite the encouraging news, the chal-
lenges posed by prions to human and animal
health are far from over. Not only do we lack
answers to many basic questions in the prion
ﬁeld, but we are also confronted with novel,
emerging problems in the human medical and
veterinary realms.
The United States has witnessed an enig-
matic rise of chronic wasting disease (CWD)
cases affecting elk and deer (7), as well as
the occurrence of the ﬁrst cases of BSE (8).
Furthermore, there has been a recrudescence
of scrapie outbreaks among European sheep
ﬂocks (e.g., Sweden, Austria, Sardinia). The
resurgence of new cases might be linked to
an increased sensitivity and frequency of the
currently executed testing procedures. These
data also underline our deﬁcit in knowledge
about prion epidemiology and possible trans-
mission routes of prion diseases in humans and
animals.
As an example in the ﬁeld of human
medicine, four cases of vCJD have been re-
ported to be caused by blood transfusion (9–
11). This indicates that BSE prions can be
recycled among humans, which has caused
considerable alarm that the supply of blood-
derived pharmaceuticals may be threatened
(12). In particular, the report of a subclini-
cal blood-derived vCJD infection in an in-
dividual carrying a heterozygote methion-
ine/valine polymorphism at codon 129 of the
human PRNP gene (10) suggests that trans-
mission of BSE prions to humans enhances
their virulence and broadens the spectrum
of susceptible recipients. In this respect, it
has been demonstrated that polymorphisms
at codon 129 of the human PRNP gene con-
trol susceptibility and incubation time in hu-
man patients (e.g., 129MM versus 129MV or
129VV drastically increases the susceptibility
of humans to BSE prions). It was reported
only recently that most individuals who suf-
fered from kuru and were polymorphic at
codon 129 showed incubation times longer
than 50 years (13).
Moreover, recent reports indicate that
there is still a lot to be learned about the
mechanisms of prion transmission (e.g., hu-
man to human or within scrapie-affected an-
imal ﬂocks) and prion tropism underlining
12 Aguzzi · Sigurdson · Heikenwaelder
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the complex alternating distribution patterns
of PrPSc (e.g., PrPSc deposition in lymphoid
tissue, the CNS) and prion infectivity un-
der varying conditions (e.g., chronic inﬂam-
mation) and hosts (e.g., sheep, elk and deer,
human): Chronic inﬂammation can alter the
tropism of prion infectivity or PrPSc to or-
gans hitherto believed prion free (e.g., liver,
pancreas, kidney of mice, mammary gland
of sheep, muscle of humans) (14–16). More-
over, PrPSc was reported in spleen and mus-
cle tissue of sporadic Creutzfeldt-Jakob dis-
ease (sCJD) patients (17), and prion infectivity
was demonstrated in muscle, blood, and saliva
of deer suffering from CWD (18, 189). Also,
prion infectivity was shown to be excreted via
urine of prion-infected nephritic mice, a pro-
cess deﬁned as prionuria (19).
These results emphasize the need for fur-
ther assessment of possible public health risks
from TSE-affected extraneural organs. It is
very well possible that preexisting pathophys-
iological conditions of the infected host ad-
ditionally contributed to unexpected distribu-
tion patterns of prion infectivity. For example,
the presence of prion infectivity in the blood
of sheep or deer may inﬂuence the deposition
of prion infectivity in various organs previ-
ously deemed prion free. Therefore, it should
be carefully reconsidered whether only organs
of the CNS and the lymphoreticular system
should be included in the current risk classi-
ﬁcations of biologicals in the future. It will be
important to test altered prion tropism pro-
ﬁles in nonlymphoid organs and body ﬂuids
(e.g., blood, urine, milk, saliva) of ruminants
(e.g., sheep, goat, cattle, elk, and deer) and hu-
man patients suffering from sCJD and vCJD.
In addition to the eminent questions of
the mechanisms of prion transmissions within
herds of ruminants, a number of looming
questions about the safety of foods and drugs
with regard to prion contamination remain
unanswered. Moreover, many aspects of the
basic biology of prions are essentially unclear.
For instance, there is very little understanding
of the mechanisms of prion replication at the
molecular level. Also, the mechanisms under-
lying the phenomena of prion strains, prion
neurotoxicity, and horizontal prion transmis-
sion remain sketchy at best. Diagnostic tools
to detect prions with consistent, high sensi-
tivity are still pending; in particular, no test
is currently available that can detect prion in-
fectivity in human blood. However, prion sci-
ence has attracted a vibrant research commu-
nity that has made scientiﬁc and technological
inroads in recent years.
For the reasons described above, prion
diseases still present a major challenge for
biomedical and basic research, representing
a fascinating biological phenomenon that has
elicited a tremendous interdisciplinary re-
search effort at the interface between neu-
roscience, structural and molecular biology,
and neuroimmunology. The fact that proteins
impart their conformational information on
other proteins, replicate in the periphery of
the infected host, and transmigrate into the
CNS, where they induce a fatal neurodegen-
erative disease, has formed a new dogma. It is
very likely that similar posttranslational mod-
iﬁcations occur in many different proteins
routinely in eukaryotic and prokaryotic cells.
These modiﬁcations may not always be nox-
ious, and may instead constitute a regulatory
process of posttranslational processing inﬂu-
encing function, aggregation status, stability,
or subcellular localization of many proteins.
Similar phenomena were found for some pro-
teins in yeast and fungi (20).
THE CELLULAR PRION
PROTEIN
The cellular prion protein (PrPC) is a glycosyl
phosphatidyl inositol (GPI)-linked glycopro-
tein undergoing facultative N-linked glyco-
sylation at two sites. Like other GPI-linked
proteins, it is enriched in detergent-resistant
membranes. The structures of mature PrPC
from mouse, human, cattle, and Syrian ham-
ster share common features: a long, ﬂexible
N-terminal tail (residues 23–128), three α-
helices, and a two-stranded antiparallel β-
sheet that ﬂanks the ﬁrst α-helix (Figure 2a
www.annualreviews.org • Molecular Mechanisms of Prion Pathogenesis 13
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and 2b) (21). The second β-sheet and the third
α-helix are connected by a large loop with
interesting structural properties. This loop is
extremely ﬂexible in most species, but it is al-
most entirely rigid in the prion protein of elk
and deer (22). It remains to be seen whether
this structural peculiarity is in any way con-
nected to the propensity of elk and deer to
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develop CWD. The carboxyl terminus of
PrPC is stabilized by a disulﬁde bond link-
ing helices two and three (Figure 2a and 2b)
(23).
Even if the N-terminal portion of the
molecule appears unstructured, it contains
two deﬁned, conserved regions. The ﬁrst con-
sists of a segment with ﬁve repeats of an oc-
tameric amino acid sequence (octapeptide re-
peat region) (Figure 2a) (21). This region
has been proposed to be important in cop-
per binding and might be somehow involved
in prion pathogenesis (26). The second re-
gion, downstream relative to the ﬁrst region,
contains a highly hydrophobic and conserved
proﬁle, which was originally termed trans-
membrane region 1. However, as it is un-
clear whether this domain really functions as
a transmembrane region under physiologi-
cal conditions, we propose to rename this re-
gion the hydrophobic core domain. It is pre-
ceded by a hydrophilic domain termed charge
cluster (Figure 2a).
PrPC is a highly conserved protein in mam-
mals, and paralogs are present in turtles (27)
and possibly even in amphibians (28). No
natural Prnp-null alleles have been described
in any mammalian species. The broad, di-
verse, developmentally regulated (29) expres-
sion pattern of PrPC in skeletal muscle, kid-
ney, heart, secondary lymphoid organs, and
the CNS suggests a conserved and broad func-
tion (30, 31). Within the CNS, high PrPC
expression levels can be detected in synaptic
membranes of neurons, but PrPC is also ex-
pressed in astrocytes (32). In the periphery,
PrPC expression is reported on lymphocytes
and at high levels on follicular dendritic cells
(FDCs) (30).
WHAT IS THE PHYSIOLOGICAL
FUNCTION OF PrPC?
The Prnp gene was identiﬁed in 1986 (33) and
Prnp knockout mice have existed since 1992
(34), yet the function of PrPC has not been
fully clariﬁed. Many recent experiments have
focused on elucidating various characteristics
of the infectious prion agent, but there have
been even more attempts to deﬁne the physi-
ological function of the PrPC. Wu¨thrich and
many others have suggested that the phys-
iological role of PrPC may help in under-
standing the pathophysiological properties of
prions in general (35). Many different func-
tions have been attributed to PrPC, including
immunoregulation, signal transduction, cop-
per binding, synaptic transmission, induction
of apoptosis or protection against apoptotic
stimuli, and many others (30). Importantly,
postnatal depletion of PrPC in neurons does
not result in neurodegeneration (36). How-
ever, neuronal apoptosis in the hippocampus
and cerebellum was observed following in-
tracranial delivery of monoclonal PrP anti-
bodies in vivo (37). Only dimerization of PrPC
was shown to induce this phenotype, point-
ing to the fact that PrPC dimerization induces
an apoptotic signal. Moreover, caspase-12 and
endoplasmic reticulum stress were reported
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Figure 1
Incidence of bovine spongiform encephalopathy (BSE) and variant of Creutzfeldt-Jakob disease (vCJD)
cases reported worldwide. (a) Reported BSE cases in the United Kingdom and in countries and states
excluding the United Kingdom. Non–United Kingdom BSE cases include cases from countries of the
European Union and outside the European Union (Canada, Israel, Liechtenstein, Japan, Switzerland,
and the United States). Data are as of the end of 2005 and also include imported cases (4). (b) Reported
cases of vCJD in the United Kingdom and in countries outside the United Kingdom. Non–United
Kingdom vCJD cases include cases reported in France, the Republic of Ireland, Italy, the United States,
Canada, Saudi Arabia, Japan, Netherlands, Portugal, and Spain. Data are as of October 2006, including
cases of vCJD patients with a residential history in the United Kingdom in the 1980s and 1990s (5). Note
that since 2005, the incidence of vCJD in France has surpassed that of the United Kingdom. Reprinted
by permission from Macmillan Publishers Ltd: Nat. Rev. Mol. Cell. Biol. 8:552–61, copyright 2007.
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a
b
PK
CC
Signal OR MAPK-resistant fragment
HC
CHO
Biochemical properties
PrPC
Rich in α-helices
Soluble
PK sensitiveO
No aggregation
Rich in β-sheets
Insoluble
PK resistant
Aggregation
PrPSc
N-181
CHO
S-S
GPI
N-197
1 22
51 231 254
232
90
Disordered
NMR structure
Well-ordered
NMR structure
111 134 179 214
23
NH
Loop
Mannose
Glucosamine
N-acetylgalactosamine
+NH3
H3N
+
Lipid bilayer 
Figure 2
Structural features and biochemical properties of the cellular prion protein. (a) Scheme of the primary
structure of the cellular prion protein and its posttranslational modiﬁcations. A secretory signal peptide
resides at the extreme N terminus. The numbers describe the positions of the respective amino acids.
The proteinase K (PK)-resistant core of PrPSc is depicted in gray; the approximate cutting site of PK
within PrPSc is indicated by arrows. CC (pink), charged cluster; HC (green), hydrophobic core; S-S, single
disulﬁde bridge; MA, membrane anchor region; GPI, glycosyl phosphatidyl inositol; CHO, facultative
glycosylation sites; NMR nuclear magnetic resonance. (b) Tertiary structure of the cellular prion protein,
as deduced from NMR spectroscopy, inserted into a lipid bilayer, including the unstructured N-terminal
tail (gray) and the GPI anchor. The α-helices are indicated in red; the antiparallel β-sheets are shown in
turquoise. Sugar residues are shown as colored small circles. See ﬁgure for biochemical properties of
PrPC and PrPSc. Figure adapted with permission from References 24 and 25.
to mediate neurotoxicity of the pathological
prion protein in vitro (38).
In addition to the expression of PrPC in
the CNS, on circulating (e.g., T and B cells)
and resident cells of the immune system (e.g.,
FDCs), PrPC is also expressed on long-term
repopulating hematopoietic stem cells (39).
There it is believed to positively regulate the
proliferation of neural precursors during de-
velopmental and adult mammalian neuroge-
nesis (40). Whatever the function of PrPC is,
upon conversion to PrPSc it may be altered,
and this may constitute a plausible cause of
neurodegeneration (35).
16 Aguzzi · Sigurdson · Heikenwaelder
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A PARTNER FOR PrPC: DATING
THE PROTEOME
In addition to the unknown function of PrPC,
prionologists are occupied with another cru-
cial question: What are the interaction part-
ners of PrPC? Finding a speciﬁc interaction
partner of PrPC might not only be an impor-
tant step forward in explaining PrPC func-
tion, it might also help explain the role of
PrPC and PrPSc in the induction of neurode-
generation. Many efforts have been under-
taken to ﬁnd interaction partners of PrPC
and indeed many have been found (N-CAM,
laminin receptor, Bax, Bcl-2, etc.) in vitro
and in vivo (41–43). However, none of the
candidates was so far demonstrated to be of
importance in vivo (30, 35), and none of
the identiﬁed interaction partners has been
shown to be implicated in prion pathogen-
esis. Therefore, one has to conclude that a
clear understanding of the physiological func-
tion of the PrPC and its interaction partners
is still lacking. The most important discov-
eries in this respect are therefore still to be
made.
MODELS DESCRIBING
THE NATURE OF THE
PRION PROTEIN AND
ITS REPLICATION
The unusual properties of the scrapie agent,
such as resistance to UV light, partial re-
sistance to proteinase K (PK), high-pressure
treatment, and high temperature, led to spec-
ulations that it might consist of protein only
(44), or be devoid of both nucleic acid and
protein (45), or be a polysaccharide (46) or a
membrane fragment (47).
At present, many hypotheses concerning
the nature of the scrapie agent have been dis-
proved, and the most commonly discussed hy-
potheses are outlined here: (a) the protein-
only hypothesis, (b) the virino hypothesis, and
(c) the hypothesis that stoichiometric trans-
formation of PrPC to PrPSc in vitro requires
speciﬁc RNA molecules.
The protein only hypothesis (44) is cur-
rently the most widely accepted model, even
though data and scientiﬁc opinions do not ab-
solutely conform to this idea (35). As outlined
in general terms by Grifﬁth (44), character-
ized in detailed form by Prusiner (48–51), and
reﬁned by Weissmann (52), it suggests that the
infectious agent causing TSE is devoid of nu-
cleic acid and is identical to a posttranslation-
ally modiﬁed form (PrPSc) of a host protein
(PrPC). It is possible that it differs from the
latter only in the conformational state (53).
A large body of epidemiological and exper-
imental evidence is in line with the protein
only hypothesis, and very stringently designed
experiments have failed to disprove it (30).
Knockout mice, carrying a homozygous dele-
tion of the Prnp gene that encodes PrPC, fail to
develop disease upon inoculation with infec-
tious brain homogenate (54) and do not carry
prion infectivity in the brain (55). Reintro-
duction of Prnp by transgenesis restores in-
fectibility and prion pathogenesis in Prnpo/o
mice (30). Additionally, all familial cases of
human TSEs are characterized by PRNP mu-
tations (56). This clearly suggests that PrPC or
mutations thereof are necessary for the devel-
opment of prion disease. On the basis of this,
two different theories explaining the mecha-
nism of PrPSc-induced conversion of PrPC to
PrPSc exist: (a) the heterodimer, or template-
directed refolding, model (57, 58) and (b) the
noncatalytic nucleated polymerization model
(59).
The template-directed refolding model
(Figure 3) proposes that upon infection of an
appropriate host cell, the incoming conforma-
tionally altered PrPC (PrPSc) starts a catalytic
cascade using PrPC or a partially unfolded
intermediate (PrP∗) arising from stochas-
tic ﬂuctuations in PrPC conformations, as a
substrate, converting it by a conformational
change into a new β-sheet-rich protein (see
also Figure 2b). The newly formed PrPSc
will in turn convert a new PrPC molecule
into a new PK-resistant entity. The con-
formational change is kinetically controlled:
A high-activation energy barrier prevents
www.annualreviews.org • Molecular Mechanisms of Prion Pathogenesis 17
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N
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PrPSc
N
PrPSc
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C N
PrPC-PrPSc
heterodimer
N N
PrPSc-PrPSc  dimerPrPC PrPSc
PrPSc protofibril
Figure 3
Models of PrPC to PrPSc conversion. (a) The antibodies POM3 and POM2 (62) are indicated in black
and red, respectively. In the case of murine PrPC and the Rocky Mountain Laboratory prion strain
(RML), POM2 binds an epitope on the N terminus of PrPC (62) that is also present on PrPSc. In
contrast, upon conversion from PrPC to PrPSc, the POM3 epitope is buried, and therefore accessible
only on the PrPC molecule. (b) The noncatalytic nucleated polymerization model proposes that the
conformational change of PrPC into PrPSc is thermodynamically controlled: The conversion of PrPC
and PrPSc is a reversible process, but at equilibrium strongly favors the conformation of PrPC.
Converted PrPSc is maintained only when it adds onto a ﬁbril-like seed or aggregate of PrPSc. Once a
seed is present, further monomer addition is accelerated.
spontaneous conversion at detectable rates.
The formation of a PrPC into a PrPSc het-
eromeric complex (PrP dimer) may lower the
activation energy barrier to the formation of
new PrPSc from PrPC-PrPSc, leading to fur-
ther recruitment of PrPC, which is an auto-
catalytic process. The extensive unfolding and
refolding process is believed to require chap-
erone activity and energy. Sporadic cases of
CJD are thought to be caused by an extremely
rare spontaneous conversion of PrPC to the
pathogenic conformation without degrada-
tion, with a frequency of about one case per
million people per year, as estimated from
CJD epidemiology (60). The familial forms of
prion disease are tightly linked to certain mu-
tations in the PRNP gene (61). Prusiner (61)
proposed that these mutations allow sponta-
neous conversion of PrPC into PrPSc with a
frequency sufﬁcient to allow the disease to be
expressed within the lifetime of the individ-
ual. This increase in probability could be due
to lowered activation energy for the transition
of the normal to the pathogenic conformation
of mutated as compared to wild-type PrP, as
proposed above.
The activation energy to switch from PrPC
to PrPSc, once the initial event has taken place,
would be far lower, taking in account the cat-
alytic nature of the further process. Alterna-
tively, the noncatalytic nucleated polymeriza-
tion model proposes that the conformational
change is thermodynamically controlled: The
conversion of PrPC and PrPSc is a reversible
process, but at equilibrium strongly favors the
conformation of PrPC. Converted PrPSc is
established and stabilized only when it adds
onto a crystal-like seed or aggregate of PrPSc
(Figure 3b). Once a seed is present, further
monomer addition is accelerated. According
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to this nucleation hypothesis, the aggregated
state would be an intrinsic property of infec-
tivity: Monomeric PrPSc would be harmless,
but might be prone to incorporate nascent
PrPSc aggregates (e.g., generating oligomeric
PrPSc).
The ﬁnal proof for the protein only
hypothesis would be, for example, the con-
version of noninfectious PrPC into infectious
material by biochemical and/or physicochem-
ical interventions as well as by expressing
truncated PrPC in vitro (e.g., in eukaryotic
or prokaryotic expression systems). In vitro
conversion of radioactively labeled PrPC into
partially PK-resistant (PrPSc) material was
performed by Bessen, Kocisko, Caughey,
and collaborators (63, 64), and brought
direct evidence that PrPSc can induce its own
formation. However, the large amounts of the
infectious agent used in this assay currently
preclude attempts to search for an increase in
infectivity (de novo infectivity) in the in vitro
conversion products. Moreover, infectivity
was never associated with the PK-resistant
isoform converted in vitro (65).
In addition, two studies recently provided
strong evidence that prions may be synthe-
sized in cell-free systems (66, 67), essentially
settling the score as to the nature of the
infectious agent. However, the molecular
mechanisms of the conversion process—for
example, how this is accomplished under
physiological conditions (e.g., pH condi-
tions, cofactors) and exactly where it takes
place in an in vivo setting (e.g., on the cell
surface, in endosomes, in the extracellular
space)—remain elusive.
The virino hypothesis (68, 69) postulates
that the infectious agent consists of an essen-
tial scrapie-speciﬁc nucleic acid associated or
coated with a host-encoded protein, for which
PrPC is the most likely candidate. The host
origin of the postulated coat would explain
the lack or reduced degree of immunological
and inﬂammatory response, whereas the ex-
istence of a nucleic acid would explain how
many different strains of scrapie can be prop-
agated in a single inbred mouse line. A tight
interaction of nucleic acid genome and PrPC
coat, which might cause the infectious parti-
cle to be compact and small, could determine
the unusual physical resistance of the parti-
cle to sterilizing procedures and chemical and
biochemical treatments. Despite considerable
efforts and the high sensitivity of the tools
of modern molecular biology, no evidence
for TSE-speciﬁc nucleic acids has yet been
adduced (30, 70, 71).
Recently it has been reported that stoi-
chiometric transformation of PrPC to PrPSc
in vitro requires speciﬁc RNA molecules (72).
Notably, whereas mammalian RNA prepara-
tions stimulate in vitro ampliﬁcation of PrPSc,
RNA preparations from invertebrate species
do not. These ﬁndings suggest that host-
encoded stimulatory RNA molecules may
have a role in the pathogenesis of prion dis-
ease. Nevertheless, it must be stated that
all experiments supporting the latter hy-
pothesis were conducted in vitro. Therefore,
these results need to be conﬁrmed in vivo
(30).
PATHOLOGY OF HUMAN PRION
DISEASES
Rapidly progressive dementia, myoclonus,
visual or cerebellar signs, pyramidal/
extrapyramidal signs, and akinetic mutism
clinically characterize fatal neurological
diseases caused by prions. The most common
human prion disease is CJD, of which there
are three subtypes: sporadic, infectious, and
familial.
All CJD subtypes have in most cases been
successfully transmitted to primates by in-
gestion or inoculation of brain tissue (30,
73, 74), thus fulﬁlling one of the main char-
acteristics of TSE diseases. The transmit-
ted/iatrogenic group consists of kuru, ia-
trogenic CJD, and vCJD. For kuru and
iatrogenic CJD, patients were exposed to the
TSE agent by contact with brain tissues or
contaminated tissue, whereas for vCJD, it is
believed that this disease is associated with
BSE, on the basis of epidemiological evidence
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and biochemical similarities of the prion
strains.
Sporadic Creutzfeldt-Jakob Disease
Approximately 85% of all human prion dis-
eases are sporadic forms of CJD. In coun-
tries that engage in meticulous surveillance,
incidences of 0.4–1.8 cases per million people
per year are reported (75). For sCJD, there is
no association with a mutant PrP allele, nor
is there any epidemiological evidence for ex-
posure to a TSE agent through contact with
people or animals infected with TSEs. How-
ever, heterozygosity (Met/Val) at PrP codon
129 appears to be associated with a lower
risk (76) and/or prolonged incubation time
(10, 13). The lack of routine laboratory test-
ing for preclinical diagnosis makes the search
for agent sources and other risk factors ex-
tremely difﬁcult. At present, the means of ac-
quisition of a TSE agent in these patients re-
mains a mystery. So far, there is no evidence
for spontaneous PrPSc formation in any an-
imal or human TSE. In humans, the peak
age incidence of sporadic CJD is 55–60 years.
However, if spontaneous misfolding were the
primary event, one might expect a continu-
ously increasing incidence with age because
more time would allow more opportunity for
rare misfolding events.
Kuru
Kuru was and still is a slowly progressing neu-
rodegenerative disease in the eastern high-
lands of Papua New Guinea, described at
the beginning of the last century. It was the
ﬁrst human disease related to scrapie (74)
when it was recognized that the lesions in
the brains of patients were similar to those
observed in scrapie. It was hypothesized that
the propagation of kuru through the soci-
ety occurred by ritual cannibalism and may
have originated with the consumption of tis-
sues that belonged to a sporadic CJD suf-
ferer (77, 78). Successful transmission of kuru-
affected brains to chimpanzees (74) indicated
an infectious agent as the cause of the dis-
ease. The incidence of kuru has decreased to
low levels upon cessation of cannibalistic rit-
uals. It has been proposed that variations in
the human prion gene (PRNP) that protect
against prion infection (e.g., heterozygosity
at codon 129) have disseminated more efﬁ-
ciently among human populations than non-
protective polymorphisms, suggesting selec-
tive pressure. Consequently, prion diseases,
now exceedingly rare, may have ravaged hu-
man populations in the distant past (79). How-
ever, several publications have pointed out
that these conclusions may be incorrect (80–
82). It was recently described that incubation
periods of kuru could be as long as 56 years.
PRNP analysis showed that most of those pa-
tients with kuru were heterozygous at poly-
morphic codon 129, a genotype associated
with extended incubation periods and resis-
tance to prion disease (13).
Iatrogenic Creutzfeldt-Jakob Disease
Iatrogenic CJD has been induced by trans-
plantation of corneal or dural tissue from pa-
tients with TSE, or by neurosurgery, using
instruments incompletely sterilized following
use on TSE patients (30). Moreover, iatro-
genic CJD has been detected after inoculation
of a growth hormone extracted from pituitary
glands pooled from large groups of individu-
als (83). In these circumstances, the extracts
were apparently contaminated with brain tis-
sue from an undiagnosed CJD patient. The
incubation period, or latent period (time from
exposure to the agent until clinical onset), is
long, ranging from two years to greater than
10 years. Interestingly, in disease following
corneal or dural transplant or the use of con-
taminated neurosurgical instruments, the la-
tency is considerably shorter (1–2 years). It
is likely that direct introduction of the agent
into the brain, as in the latter instances, may
account for the clinical differences (e.g., in in-
cubation period and clinical signs) observed.
Houston and colleagues (84) demonstrated
that is possible to efﬁciently transmit prions
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via blood transfusion in sheep. This route of
potential transmission represents a scenario
for inadvertent ampliﬁcation of the new vCJD
agent to humans, which was, until recently,
thought to be purely hypothetical. However,
recent reports present cases where exactly that
may have happened (9–11, 85). The ﬁrst pa-
tient was identiﬁed to have developed symp-
toms of vCJD most likely as a consequence of
blood transfusion received from an individ-
ual harboring the vCJD agent 3.5 years prior
to developing clinical signs of prion disease
(9). Six and a half years post blood transfu-
sion, the recipient developed clinical signs of
prion disease (9). These ﬁndings raised the
likely possibility that infection was transfusion
transmitted.
Variant Creutzfeldt-Jakob Disease
In 1996, neuropathologists in the United
Kingdom described vCJD (3). This disease is
not a familial disease associated with muta-
tions in the PRNP gene as described below. To
date, all primary vCJD cases are found to carry
the Met/Met allelotype at PrP codon 129, a
common genotype in the Caucasian popula-
tion. vCJD affects primarily young adults and
is clinically characterized as a progressive neu-
ropsychiatric disorder leading to ataxia, de-
mentia, and involuntary movements. vCJD
can be distinguished from sCJD, the most
common human TSE recognized worldwide
for decades, by the early age of onset (vCJD:
19–39 years; sCJD: 55–60 years), longer
duration of illness (vCJD: 7.5–22 months;
sCJD: 2.5–6.5 months), absence of electroen-
cephalographic changes typically found in
CJD, and distinct neuropathological features
(86). In vCJD, signiﬁcant amounts of patho-
logical prion protein (PrPSc) are detectable
in the lymphoid tissues in preclinical disease
(87). Of note, PrPSc is also detectable in lym-
phoid tissues and extralymphoid tissues of
sporadic CJD patients by western blotting and
immunohistochemistry (17).
The initial occurrence of these patients
in the United Kingdom indicated a possi-
ble association with BSE in cattle (3). Subse-
quent laboratory experiments demonstrated
a strong similarity between BSE and vCJD
on the basis of similar lesion distributions in
mouse brains, PrPSc glycoform gel banding
patterns, and neuropathology after transmis-
sion to cynomolgus macaques (Macaca fascicu-
laris) (88–90). On the basis of these data, vCJD
likely represents a spread of BSE from cattle
to humans.
Although millions of Europeans were most
likely exposed to BSE, only approximately 200
humans have contracted vCJD in past years.
Although most cases have been reported in the
United Kingdom, other European and non-
European countries including France, Italy,
and Canada still have cases of vCJD. There-
fore, susceptibility may be controlled by en-
dogenous or exogenous factors.
Since 2001, however, the incidence of
vCJD in the United Kingdom appears
to be stabilizing (http://www.cjd.ed.ac.uk/
vcjdworld.htm). It may be too early to draw
any far-reaching conclusions on the extent of
the CJD epidemic, but each year that passes
without any dramatic rise in the number of
cases increases the hope that the total num-
ber of vCJD victims will be limited (91). The
incidence of vCJD in the United Kingdom
may already be subsiding (Figure 1b)
(92).
At present, there is concern that some in-
dividuals exposed to BSE might be asymp-
tomatic carriers of the infection (93) and that
these people might, in turn, pose a risk of fur-
ther transmission of the infection to others
(e.g., blood transfusions, donors for corneal
transplantations). Because of this, there has
been an increased need to develop adequate
sterilization procedures for surgical instru-
ments, as conventional sterilization proce-
dures do not completely abolish infectivity.
Moreover, concern that the blood supply
might be contaminated with the vCJD agent,
as discussed above, has been widely publi-
cized. Many countries have, therefore, passed
rules to diminish the use of blood from donors
who might have been exposed to BSE/vCJD
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in the United Kingdom during the peak of the
BSE epidemic.
Familial Transmissible Spongiform
Encephalopathies
Familial TSEs are associated with an auto-
somal dominant PRNP gene alteration (94).
This disease accounts for 10%–20% of all
TSE cases in humans and includes familial
CJD, Gerstmann-Stra¨ussler-Scheinker (GSS)
syndrome, and fatal familial insomnia. There
is variability in the clinical and pathological
ﬁndings, the age of onset, and the duration
depending upon the particular PrP mutation
involved. In addition to point mutations in the
PRNP gene, insertions in the octapeptide re-
peat region (Figure 2) of the PRNP gene have
been associated with degenerative brain dis-
ease. Clinical disease usually begins at an early
age and is of a long duration. GSS syndrome
is a rare inherited autosomal dominant dis-
ease, which is associated with mutations in the
PRNP gene (the most common are at codons
102 and 198). GSS syndrome is characterized
by chronic progressive ataxia, terminal de-
mentia, a long clinical duration (2–10 years),
and multicentric amyloid plaques that can be
visualized by antibodies directed against the
prion protein. Fatal familial insomnia is an
inherited disease, which is characterized by
sleep disturbances as well as vegetative and
focal neurological signs as a result of thalamic
lesions. The clinical phenotype depends upon
the D178N point mutation of the PRNP gene
coupled with a methionine at codon 129 (95).
NEUROTOXICITY,
INFECTIVITY, AND PrPSc
It is clear that prions exert their destruc-
tive effects predominantly, if not exclusively,
within the CNS. However, the proximal cause
of neurotoxicity remains unclear. PrPC is re-
quired for prion replication, as mice devoid
of PrPC are resistant to prions (54). Dimeric
PrPC was found to efﬁcaciously bind PrPSc
(96), suggesting that its conversion is some-
how instructed by PrPC. The ﬁrst evidence for
PrPC-mediated neurotoxicity was provided by
grafting neural tissue overexpressing PrPC
into the brain of PrP-deﬁcient mice (97). After
intracerebral inoculation with scrapie prions,
grafts accumulated high levels of PrPSc and
infectivity, developing characteristic scrapie
histopathology. It was then reported that de-
pletion of endogenous neuronal PrPC in mice
with established prion infection reversed early
spongiform changes and banned neuronal loss
and progression to clinical disease (98).
PrPC depletion during the conversion pro-
cess is unlikely to cause pathology because
ablation of PrPC does not result in scrapie-
like symptoms (34). This is corroborated by
postnatal PrPC depletion, which does not re-
sult in neurodegeneration (36). However, it
could be possible that PrPC function is al-
tered upon conversion to PrPSc, leading to
neurodegeneration (30, 35). Although neuro-
toxic, quite surprisingly, high prion titers in
lymphoid organs are not accompanied by sig-
niﬁcant histopathological changes (99, 100),
even though murine scrapie infection was re-
cently reported to cause an abnormal germinal
center reaction in the spleen (101).
Expression of a PrP variant targeted to
the cytosol was found to be toxic to cultured
cells and transgenic mice, and it was specu-
lated that this feature might be common to
diverse prion-related neurodegenerative dis-
orders (102, 103). Mutant PrPC, lacking GPI
anchor and its signal peptide, retrogradely
transported out of the endoplasmatic retic-
ulum induced the generation of amorphous
PrP aggregates that possessed partial PK re-
sistance in the cytosol (103). The disease was
not reported to be transmissible, which is, af-
ter all, the crucial deﬁning trait of a prion dis-
ease. Subsequent reports have argued against
the contribution of a cytosolic neurotoxic PrP
species to prion pathology (104), and there-
fore this question should be considered unre-
solved at the present stage.
Transgenic mice expressing N-terminal-
deleted variants of PrP were found to suf-
fer from unexpected phenotypes, including
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cerebellar granular cell degeneration and
leukoencephalopathy (105, 106). Deletions of
amino acids 32–121 or 32–134 (collectively
termed PrP) confer strong neurotoxicity to
PrPC in vivo, a pathology that can be ab-
rogated by reintroduction of wild-type, full-
length PrPC (105). The latter phenomenon
suggests that PrP is a functional antagonist
of PrPC. If so, suppression of PrP toxicity
may be used for probing the functional in-
tegrity of PrP mutants. This strategy has been
used extensively by us and others, as it al-
lows one to map functional domains within
the Prnp gene, even if the function of PrP is
still not understood.
PrPC contains a highly hydrophobic
stretch at the border between its ﬂexi-
ble N-terminal and its globular C-terminal
part. This particular stretch is believed to
play an important functional role, and its
manipulation may provide signiﬁcant func-
tional insights: Recent studies suggest that
a small deletion within this hydrophobic
stretch (amino acids 121–134) sufﬁces to pro-
duce a highly neurotoxic molecule (107). An-
other neurotoxic type of PrP was reported
by Hegde et al. (108), who discovered that
the hydrophobic domain acquires a trans-
membrane localization in a small fraction of
PrP molecules in contrast to abundantly GPI-
anchored PrP molecules. Expression levels of
transmembrane PrP (CtmPrP) are elevated in
certain pathogenic PrP mutants, which are
neurotoxic when expressed at high levels in
transgenic animals (109). Surprisingly, when
co-expressed with full-length PrP, CtmPrP
is even more neurotoxic. In this regard, it
behaves very differently from N-terminally
truncated PrP, whose toxicity is reduced or
abolished by the expression of full-length
PrP.
Although the normal function of PrP is
presumed beneﬁcial, there is a growing list
of malicious consequences beyond prion dis-
eases that can be elicited by manipulating PrP.
Such consequences encompass not only the
neurological syndrome (termed Shmerling’s
disease) elicited by PrP family members.
It was also found that antibody-mediated
cross-linking of PrP in vivo triggers neuronal
apoptosis in the hippocampus and cerebellum
(37). This effect was induced by dimerization
of PrPC through the intracranial stereotaxic
delivery of bivalent immunoglobulins. None
of the molecular mechanisms underlying
these observations have been elucidated, but
there has been much speculation that cross-
linking may induce cytotoxic lethal signaling
cascades. Recently, Chesebro and colleagues
generated an interesting Prnp transgene that
lacks the signal peptide responsible for GPI
anchoring (110). Consequently, transgenic
mice expressed exclusively a secreted form
of PrPC. Although GPI-negative transgenic
mice did not develop clinical disease upon
prion infection, their brains contained PrPSc
plaques. Evidently, removal of the GPI
anchor abolished the susceptibility to clinical
disease while preserving the competence of
the soluble PrPC molecule to support prion
replication (110). This observation ﬁts with
the growing body of evidence that PrPC may
function as a signaling molecule, just like
other GPI-linked proteins (111).
Additionally, the brain, blood, and heart
of GPI-negative transgenic mice contained
both abnormal protease-resistant prion pro-
tein as well as prion infectivity (112). Blood
plasma of GPI-negative transgenic mice was
found to be infectious (>7 log LD50 infec-
tious units ml−1) (112), mimicking a situa-
tion of blood-borne prion infectivity as known
from scrapie sick sheep (84), chronic wasting
diseased elk and deer (18), and vCJD patients
(9, 10). Interestingly, the hearts of these trans-
genic mice contained PrPSc-positive amyloid
deposits, leading to myocardial stiffness and
cardiac disease (112).
Although the exact composition of the in-
fectious prion agent remains elusive, the size
of the most infectious moiety was determined
(113). The PK-resistant core of PrPSc was par-
tially disaggregated, fractionated by size, and
analyzed by light scattering and nondenatur-
ing gel electrophoresis. Analyses revealed that
nonﬁbrillar particles, with masses equivalent
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to 14–28 PrP molecules, are the most infec-
tious particles. These very exciting data sug-
gest that the Ur prion is indeed an oligomeric
seed, that is, a small, ordered aggregate that
possesses the capability of growing by means
of recruiting monomeric PrP further into
itself.
Harris and colleagues (114) generated
Tg [PrP–enhanced green ﬂuorescent pro-
tein (EGFP)] mice, which express an EGFP-
tagged version of the prion protein. This fu-
sion protein behaves like endogenous PrP in
terms of its posttranslational processing, sub-
cellular localization, and functional activity—
as measured by suppression of Shmerling’s
disease. Although not convertible to PrPSc
when expressed by itself, the fusion protein
was incorporated into scrapie ﬁbrils in brains
of prion-infected animals. Co-expression of
the transgene and wild-type PrP resulted in
progressive accumulation of ﬂuorescent PrP-
EGFP aggregates in neuropil, axons, and the
Golgi apparatus of neurons, upon prion inoc-
ulation. These results identiﬁed intracellular
sites of PrPSc aggregation that had not been
visualized thus far (115), and provided a novel
and potentially extremely useful reagent for
the study of PrP aggregation.
PRION PATHOGENESIS:
LESSONS FROM THE MOUSE
MODEL
PrPC itself is involved in transporting prion
infectivity from peripheral sites to the CNS.
Adoptive transfer with wild-type bone mar-
row (BM) into Prnpo/o mice reconstitutes the
capability of the spleen to accumulate high
titers of prion infectivity up to 300 dpi (116,
117). However, reconstitution experiments
with wild-type BM into Prnpo/o mice were
insufﬁcient to restore neuroinvasion. There-
fore, hematopoietic cells (e.g., B and T cells,
macrophages, and dendritic cells) facilitate the
transport of prions from peripheral entry sites
to secondary lymphoid organs, in which pri-
ons accumulate and/or replicate, although the
primary compartment for prion neuroinva-
sion appears to be nonhematopoietic because
it cannot be adoptively transferred by BM
reconstitution (116–118).
But how do prions reach the brain follow-
ing a natural route of exposure, for example,
via ingestion? And which cellular and molec-
ular preconditions enable efﬁcient transport?
These questions were studied intensively in
vitro and in vivo: An in vitro study has shown
that microfold cells, specialized intestinal ep-
ithelial cells that transfer antigens including
pathogens through the epithelium, can trans-
port infectious prions from the apical to the
basolateral surface (119). Subsequently, prion
neural entry and transit to the CNS may oc-
cur with direct prion uptake by nerve endings
in the intestine (or spleen after an intraperi-
toneal exposure) and/or possibly following an
ampliﬁcation phase in the lymphoid tissue;
Peyer’s patches are required for prion disease
development in the mouse (120). Upon in-
terference with lymphoid prion accumulation,
many studies have shown disruption and de-
lay in the development of prion disease (121,
122).
Some of the lymphoid players crucial to
peripheral prion accumulation have been re-
vealed. Clearly, functional FDCs are essential
(121, 123), but it is not entirely clear whether
they are the only site of lymphoreticular prion
replication or accumulation (116, 117). B lym-
phocytes are also necessary (118), as they pro-
vide maturation signals for FDCs. There is
an ill-characterized BM-derived cell popula-
tion that clearly supports prion replication
(117, 124), although this may not apply to
all prion strains (125). In addition, morpho-
logic evidence based on time-course studies
indicates involvement of the vagal nerve and
the sympathetic nervous system as routes of
peripheral prion transport to the CNS (126).
Glatzel et al. (127) have shown that the sym-
pathetic nervous system is essentially involved
in neuroinvasion: Mice with sympathectomy
show a signiﬁcantly prolonged incubation pe-
riod, and transgenic mice overexpressing the
nerve growth factor transgene that have sym-
pathetic hyperinnervation of lymphoid organs
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show an accelerated incubation period after a
peripheral prion exposure, illustrating the sig-
niﬁcance of these peripheral nerves in prion
pathogenesis.
In the mouse scrapie model, some forms
of immunodeﬁciency impair prion replica-
tion and delay disease development, illustrat-
ing the signiﬁcant contribution of this early
lymphoid phase. For example, severe com-
bined immunodeﬁcient mice, RAG-1−/−, and
μMT mice completely resist intraperitoneal
prion infection (118). However, replacement
of B lymphocyte populations, whether they
express PrPc or not, restores prion infectibil-
ity, possibly owing to the key role of mature B
lymphocytes in the FDC maturation by pro-
vision of tumor necrosis factor and lympho-
toxins. PrPSc heavily decorates FDC mem-
branes in secondary follicles of the spleen
(128), lymph node, tonsils, and Peyer’s patches
in several prion diseases, including vCJD,
scrapie, and CWD.
The importance of FDCs in peripheral
prion pathogenesis may be exploited for prion
prevention strategies. Inhibiting the lympho-
toxin beta receptor (LTβR) pathway in mice
and nonhuman primates by treatment with
LTβR-immunoglobulin fusion protein re-
sults in the disappearance of mature, func-
tional FDCs (129, 130). Indeed, treatment
with LTβR-immunoglobulin fusion protein
was found to impair peripheral prion patho-
genesis (121, 123, 131).
The detection of PrPSc in spleens of
sCJD patients (17) suggests that the inter-
face between cells of the immune system
and peripheral nerves might also be of rel-
evance in sporadic prion diseases. Indeed,
in mouse scrapie studies, there is no doubt
that the microarchitecture of lymphoid or-
gans crucially controls the efﬁcacy of prion
neuroinvasion: Manipulation of the distance
between FDCs and major splenic nerves af-
fects the velocity of neuroinvasion (132). By
ablation of the CXCR5 chemokine recep-
tor, lymphocytes were directed toward spe-
ciﬁc microcompartments, which reduced the
distance between germinal-center-associated
FDCs and nerve endings (133). This resulted
in an increased rate of prion entry into the
CNS in CXCR5−/− mice, most likely ow-
ing to repositioning of FDCs in juxtaposi-
tion with highly innervated, splenic arterioles.
It remains to be determined whether the in-
creased rate of neuroinvasion results from a
passive diffusion of prions [e.g., released FDC
exosomes (134, 135)] or whether mobile cells
such as dendritic cells or B cells located in the
germinal center are involved in an active pro-
cess of transport. However, the cells involved
in early transport remain unclear. Some evi-
dence for the involvement of dendritic cells
has accrued (136). However, other mobile el-
ements, including budding viruses, could also
serve as vehicles of infectivity (137).
Because FDCs bind to opsonized antigens
via the CD21/CD35 complement receptors,
is complement involved in prion pathogen-
esis? Indeed, mice that lack various comple-
ment factors including C1q (138), or that have
been depleted of the C3 complement compo-
nent (139), enjoy enhanced resistance to pe-
ripheral prion inoculation. C1q was shown
to directly bind PrP in vitro (140). Human
studies also point to a possible role for mem-
bers of the classical complement cascade in
prion pathogenesis (141); however, their pre-
cise role in prion disease is unknown.
As proinﬂammatory cytokines and im-
mune cells are involved in lymphoid prion
replication (121, 125, 132, 142), we as-
sessed whether chronic inﬂammatory condi-
tions within nonlymphoid organs could affect
the dynamics of prion distribution. Indeed, in-
clusion body myositis, which is an inﬂamma-
tory disease of the muscle, was associated with
large PrPSc deposits in muscle (16). There-
fore, mice with nephritis, hepatitis, or pan-
creatitis were inoculated with mouse prions
(Rocky Mountain Laboratory strain) and were
found to accumulate prions in these otherwise
prion-free organs. The presence of inﬂam-
matory foci consistently correlated with the
upregulation of lymphotoxins α and β (LTs)
and the ectopic induction of PrPC-expressing
FDC cells (14).
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These data raised concerns that analogous
phenomena might occur in TSE-susceptible
ruminants. Indeed, we found that sheep with
natural scrapie infections and concurrent
mastitis harbored PrPSc in their mammary
glands (15), indicating that inﬂammatory
conditions induce accumulation of prions in
organs previously believed to be prion free.
Therefore, inﬂammation might indeed be a
license for prion replication in nonlymphoid
peripheral organs (Figure 4), and other orga-
nized chronic inﬂammatory disorders could
potentially be sites of prion accumulation and
replication.
In addition, it was hypothesized that in-
ﬂammatory conditions could result in the
shedding of prions via excretory organs (e.g.,
kidney). To investigate this hypothesis, vari-
ous transgenic and spontaneous mouse mod-
els of nephritis were analyzed to ascertain
whether prions could be excreted via urine
(19). Indeed, prion infectivity was observed
in the urine of mice with both subclinical and
terminal scrapie, and with inﬂammatory con-
ditions of the kidney (19).
The genetic or environmental factors that
enable horizontal prion spread between hosts
have been perplexing. It is possible that the
horizontal spread of prions is mediated by se-
creted body ﬂuids (e.g., urine, milk) derived
from potentially infectious secretory organs
(e.g., mammary gland, kidney). Placenta of in-
fected ewes could provide a source of prion
infectivity for horizontal transmission (143).
However, the set of data supporting the latter
hypothesis is scant at best.
Public health considerations mandate that
we should increase our understanding of the
altered prion tropism observed in ruminants
(e.g., sheep, cattle, goat, elk, and deer) and
the underlying mechanisms. Future experi-
ments should include an analysis of the effect
of other common chronic inﬂammatory dis-
orders (e.g., granulomatous diseases) in prion-
infected animals.
Does a chronic subclinical disease or a per-
manent carrier status occur in ruminants or in
humans? Evidence that such a carrier status
may be produced by the passage of the infec-
tious agent across species was ﬁrst reported by
Race & Chesebro (144) and has been conﬁrm-
ed by others (145, 146), at least for the pas-
sage between hamsters and mice. Chesebro
reported that mice inoculated with hamster
prions lived a long symptom-free life and did
not accumulate detectable PrPSc (35). PrPSc-
negative mouse brains were then injected into
naive mice, which had no clinical disease for
>650 days. The brains of the latter mice were
then passaged to hamsters and resulted in
rapid lethality. Therefore, the agent had repli-
cated silently for several years, and could be
adoptively transferred, in mice without induc-
ing any clinical signs or histopathology, but
maintained full virulence toward hamsters.
Immune deﬁciency can also lead to a simi-
lar situation in which prions replicate silently
in the body, even when there is no species bar-
rier (147). So the problem of animal TSEs
could be more widespread than is assumed and
may call for drastic prion surveillance mea-
sures in farm animals, in which healthy ani-
mals are tested as well as those with clinical
signs of disease. Moreover, people carrying
the infectious agent may transmit it horizon-
tally (148), and the risks associated with this
possibility can be addressed only if we know
more about how the agent is transmitted and
how prions reach the brain from peripheral
sites.
MECHANISTIC
UNDERPINNINGS
OF PRION STRAINS
The phenomenon of prion strains has in-
trigued scientists for decades. Prion strains
are distinguishable by stable incubation peri-
ods and the pattern of histopathologic lesions
within the brain of the same host species. The
protein only hypothesis has difﬁculty explain-
ing the ﬁnding that the propagation of dif-
ferent scrapie strains in mice are homozygous
in regard to their Prnp gene (30, 35): It sug-
gests that an incoming PrPSc strain can con-
vert the same PrP precursor into a likeness of
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Figure 4
Induction of tertiary follicles and prion replication competence in nonlymphoid organs. (a) Hypothetical
hierarchical cascade inducing the generation of tertiary follicles in nonlymphoid organs and possibly
giving rise to ectopic prion replication competence. Autoimmune diseases as well as chronic lymphocytic
inﬂammatory conditions have been demonstrated to induce prion replication competence in
nonlymphoid organs (green), whereas others have not been investigated (question mark). (b) Schematic
drawing of the events that contribute to the generation of tertiary follicles in response to an inﬂammatory
stimulus that results in the attraction and activation of lymphocytes and the upregulation of
lymphotoxins α and β (LTs). LTβ receptor positive (LTβR+) stromal precursor cells, activated upon
binding to LTs (LTα3 or LTα1β2) provided by lymphocytes, lead to the expression of homeostatic
chemokines and further LTs, generating a positive feedback loop that leads to the formation of tertiary
follicles containing follicular dendritic cells and other cells of the immune system. Reprinted by
permission from Macmillan Publishers Ltd: Nat. Rev. Microbiol. 4:765–75, copyright 2006.
itself, and that this alone can create distinct
disease phenotypes, varying in clinical signs,
organ tropism, and regions of prion accumu-
lation in the brain.
It is challenging, but maybe not impossi-
ble, to reconcile these intriguing data with
Prusiner’s protein only hypothesis: Epige-
netic, posttranslational strain characteristics
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of prions appear to dominate over the primary
prion protein sequence of the infected host.
The diversity of prion strains is largely be-
lieved to be due to conformational ﬂexibility
of PrPSc. The host PrPSc structure is deter-
mined by both the PrPSc conformation in the
donor inoculum and limitations imposed by
the host primary PrP structure. Circumstan-
tial evidence suggests that strain phenotypes
may be encoded within different conforma-
tions of PrPSc with distinct properties, in-
cluding stability against chaotropic salts and
heat (149), the relative prevalence of the main
glycosylated moieties, and the size of the
PK-digested PrPSc. The strain-speciﬁc dif-
ferences in the size of PK-digested PrPSc
molecules are thought to result from individ-
ual conformations, leading to exposure of dis-
tinct cleavage sites. This was ﬁrst suggested
by experiments with transmissible mink en-
cephalopathy (TME), indicating that prion
diversity could indeed be conferred by a sin-
gle protein with varying three-dimensional
structures (150). Although great strides have
been made toward understanding the molec-
ular origin of strains, the ﬁnal proof that
conformational variants of PrPSc represent
the biological basis of prion strains is still
lacking.
Recent in vivo evidence indicated that a
similar phenomenon of conformational vari-
ants may occur in Alzheimer’s disease (151).
Here the existence of Aβ strains that can seed
and accelerate aggregation and Aβ pathol-
ogy was posited. These intriguing observa-
tions support the hypothesis that the patho-
genetic mechanisms operating in Alzheimer’s
disease and in prion diseases have more in
common than we often appreciate (152). Per-
haps future studies will address whether dif-
ferent Aβ strains with distinct biochemical or
neuropathological characteristics occur in hu-
mans. Can multiple prion strains coexist and
effect prion replication? Two subtypes of spo-
radic CJD have recently been demonstrated
to coexist in humans (62). Experimental stud-
ies have shown that when two strains infect
the same host, one strain can impede the abil-
ity of the second strain to cause disease (153).
Bartz and colleagues (154) recently suggested
that this might be caused by the suppression of
prion replication of the second strain. Strain
features are useful for tracing prion infections
between species. When transmitted to pri-
mates, BSE causes lesions strikingly similar
to that of vCJD (155, 156). BSE is most likely
transmissible to humans too, and strong cir-
cumstantial evidence (157–159) suggests that
BSE is the cause of vCJD, which has claimed
more than 200 lives in the United Kingdom
(3, 160), as well as a much smaller number in
some other countries (161).
NATURAL TRANSMISSIBLE
SPONGIFORM
ENCEPHALOPATHIES:
WHAT IS NEW?
Cattle Prions
More than a few surprises have come from
further investigations of prion strains in
ﬁeld cases of TSEs. Until recently, BSE
was believed to be associated with one sin-
gle prion strain, classiﬁed by an exclusive
and remarkably stable biochemical proﬁle of
PrPSc. However, distinct molecular signa-
tures have recently been discovered through
the large-scale screening of cattle mandated
by European authorities in the context of
BSE surveillance. These atypical proﬁles fall
into either of two groups: H-type cases of
protease-resistant fragments with a molec-
ular weight higher than BSE, and bovine
amyloidotic spongiform encephalopathy, or
L type (lower) (162). To test whether these
different biochemical and histopathological
properties correspond to distinct strains, the
Laude laboratory transmitted H-type-PrPSc
isolates from French cattle into transgenic
mice expressing bovine or ovine PrP (163).
The recipient mice developed neurological
signs exhibiting strain-speciﬁc features clearly
distinct from that of the classical BSE agent,
providing pivotal evidence that the underly-
ing strains are distinct.
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Atypical Sheep Scrapie
In 1998, aberrant cases of sheep scrapie were
described in Norway and the strain was newly
classiﬁed as Nor98 (164). Active European
Union surveillance later revealed additional
cases of atypical scrapie in several other coun-
tries (165, 166). Sheep infected with Nor98,
or atypical scrapie, accumulated PrPSc pri-
marily in the cerebellum and cerebral cor-
tex rather than in the brainstem target in the
classical strain (167). Additionally, on western
blot analysis of atypical scrapie cases, an ad-
ditional small-molecular-weight (10–12 kDa)
PrP fragment appeared after PK digestion and
was shown by epitope mapping to lack both
N and C termini of PrP (167, 168). Further-
more, atypical scrapie cases occurred not only
in the classical scrapie-susceptible genotypes
(A136 R154 Q171), but also in genotypes
associated with high resistance to classical
scrapie (A136 R154 R171) (165, 166). Were
these atypical scrapie cases also infectious? In
2001, atypical scrapie cases were shown to be
transmissible prion diseases after inoculated
ovine PrP-expressing transgenic mice devel-
oped disease and prion aggregates (169). In
the meantime, several countries appear to be
reporting extremely high incidences of atyp-
ical scrapie, and in fact atypical scrapie ap-
pears to be the rule rather than the exception
in some geographical areas.
Chronic Wasting Disease
Among all animal prion diseases, CWD of
cervids is likely the most efﬁciently trans-
mitted. CWD infections occur in mule deer
(Odocoileus hemionus), white-tailed deer (O.
virginianus), Rocky Mountain elk (Cervus ela-
phus nelsoni) (170), and moose (Alces alces shi-
rasi) (171). Prevalence can reach as high as
30% in dense, free-ranging deer populations
and nearly 100% in captive animals (171).
Hypotheses for CWD transmission range
from spread via direct contact to exposure
through grazing in areas contaminated by
prion-infected secretions, excretions (saliva,
urine, feces), tissues (placenta), or decom-
posed carcasses. Insightful experimental stud-
ies have recently revealed two key ﬁndings:
(a) Saliva from CWD-infected deer can trans-
mit disease (18), and (b) CWD-infected car-
casses allowed to decay naturally in conﬁned
pastures can lead to CWD infections in cap-
tive deer (172). Additionally, the abundant
CWD-prion accumulation within lymphoid
tissues may also lead to CWD prion buildup
in nonlymphoid organs with lymphoid folli-
cles, as was recently shown in kidney, poten-
tially shifting shedding routes (173). It is un-
known whether other types of inﬂammation,
such as the granulomatous inﬂammation in
the intestine seen in Johne’s disease (Mycobac-
terium avium subsp. paratuberculosis; affects ru-
minants, including deer and elk) or parasitic
inﬂammation, could lead to or perhaps in-
crease prion excretion by fecal routes. The
environmental prion contamination in CWD
underscores the difﬁculties of CWD disease
management. Within North America, CWD-
infected deer and elk have been detected in 14
states and two Canadian provinces (170, 174,
175).
CWD surveillance in Europe has been
more limited. However, in Germany, a to-
tal of 7300 captive and free-ranging cervids
were tested for CWD with no sign of infection
(176). Reindeer or caribou (Rangifer tarandus),
from North America or Northern Europe re-
spectively, have a highly homologous prion se-
quence compared with mule deer and thus are
likely susceptible to CWD. Other European
cervids such as moose and red deer (C. elaphus)
are also expected to be CWD susceptible.
The deer and elk primary protein struc-
tures are highly conserved, as seen in other
mammals. Interestingly, a polymorphism at
codon 225S/F may inﬂuence CWD sus-
ceptibility in mule deer. When comparing
the frequency of genotypes among CWD-
negative and -positive deer (n = 1482), the
odds that a CWD-infected animal was 225SS
was 30 times greater when compared with
225SF, whereas the frequency of 225SF/FF
genotypes in CWD-negative deer was 9.3%,
but only 0.3% in CWD-positive deer (177).
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Additionally, elk have a polymorphism at
codon 132 (M/L) of Prnp, corresponding to
polymorphic codon 129 (M/V) in humans.
Elk expressing 132ML and 132LL Prnp were
reported to be overrepresented among elk
with CWD when compared with uninfected
controls (178), and 132LL elk experimentally
infected with CWD have resisted infection
for at least four years, whereas 132MM or
132ML elk (n = 2 each) developed termi-
nal clinical prion disease by 23 or 40 months
post inoculation, respectively, conﬁrmed by
immunohistochemistry and western blotting
for PrPSc (179). White-tailed deer also have
Prnp polymorphisms that may affect their
CWD susceptibility. A reduced susceptibility
to CWD was linked to a G96S and a Q95H
polymorphism in a study comparing allelic
frequencies from CWD-positive and CWD-
negative free-ranging Wisconsin white-tailed
deer (180).
PRION STRAINS AND ORGAN
TROPISM
Deﬁnitions of prion strains ease nomencla-
ture and classiﬁcation but certainly do not ex-
plain why distinct strains have different organ
tropisms. Indeed, some prion strains favor the
CNS as a primary target organ but show low
abundance or absence in secondary lymphoid
organs (e.g., classical BSE, with gut-associated
lymphoid tissue being PrPSc positive over a
transient period of time). In contrast, other
prion strains can be detected in the CNS but,
in addition, exist to high extent in secondary
lymphoid organs (e.g., vCJD, CWD, scrapie)
(181). What deﬁnes the tropism of a prion
strain? One might speculate that tropism is
deﬁned by the tertiary and quarternary struc-
ture of prions leading to binding or interac-
tion with different molecules (e.g., receptors)
and therefore different cells. It may also be
possible that cellular binding and uptake of
prions remains unaltered, but that efﬁcient
conversion is restricted to those particular
cells that contain a cofactor compatible with
the respective strain. This would necessitate
that cofactors supporting prion conversion of
distinct strains exist in a particular cell.
Bartz and colleagues (182) analyzed the
role of prion infection of lymphoid tissues in
neuroinvasion following oral and intraperi-
toneal (i.p.) inoculation with the hyper (HY)
and drowsy (DY) prion strains of TME. DY
TME agent infectivity was not detected in
spleen or lymph nodes following i.p. or oral
inoculation. Moreover, no clinical disease was
observed following i.p. inoculation. In con-
trast, inoculation of the HY TME agent by the
i.p. and oral route resulted in splenic and nodal
prion replication, inducing clinical scrapie. To
clarify the role of the lymphoid tissue in neu-
roinvasion, the HY and DY TME agents were
inoculated into the tongue, which is highly
innervated and commonly shows lesions in ru-
minants. Following intratongue inoculation,
the DY TME agent induced prion disease,
with deposits both in the tongue and brain-
stem nuclei that innervate the tongue. No
PrPSc was found in the spleen or lymph nodes.
These data support the hypothesis that the
DY TME agent can spread from the tongue
to the brain along cranial nerves without
requiring agent replication in the lymphoid
tissue.
A major challenge in studying various
prion strains from cattle, sheep, goats, or hu-
mans is to ﬁnd the appropriate, sensitive recip-
ient bioassay, in which the respective strain of
interest or even various strains can be prop-
agated. In most cases, prion transmission of
distinct species (e.g., human prions into ham-
ster) is restricted by the species barrier, pre-
venting the characterization of, for example,
human or ovine prion strains in mouse mod-
els. Therefore, prionologists expressed PrPC
proteins of various species in transgenic mice
to enable transmission or adaptation experi-
ments (183, 184). This worked very well in
many instances of autologous PrP expression,
for example, ovine or human PrP (185, 186).
Furthermore, reduction of species barrier was
shown to be facilitated by high expression lev-
els of heterologous PrP (7). A recent study
by the Agrimi group identiﬁed an appropriate
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rodent model, the bank vole (Clethrionomys
glareolus), for efﬁcient primary prion trans-
mission of CJD isolates (187). Voles infected
with genetic and sCJD isolates reproduced
strain-speciﬁc neuropathology and accumu-
lated PrPSc with biochemical properties sim-
ilar to the human counterpart. Adaptation of
genetic CJD isolates to voles showed little
or no evidence of a transmission barrier, in
contrast to the striking barriers observed dur-
ing the transmission of mouse, hamster, and
sheep prions to voles. This is highly interest-
ing because, although low prion protein se-
quence homology between man and vole was
detected, transmission efﬁciency was com-
parable to that reported in transgenic mice
carrying a human prion protein (188). Fur-
ther experiments in this direction could in-
crease our understanding in how sequence and
three-dimensional structure and maybe co-
factors control species barrier or support the
propagation of distinct strains.
FUTURE DIRECTIONS
As discussed in this work, a lot of progress
has been accomplished in the identiﬁcation
of prion strains as well as in the understand-
ing of the neurotoxic mechanisms of prions.
Although this is extremely encouraging, the
molecular basis for neurodegenerative pro-
cesses observed in prion diseases is poorly un-
derstood. The development and appropriate
use of new tools and technologies enabled pri-
onologists in recent years to answer a couple
long-standing key questions in the ﬁeld. For
example, analysis of prion aggregates by light
scattering and nondenaturing gels deﬁned the
size of the most infectious prion particle (113).
So what are the open questions of the prion
ﬁeld? Some of the most important issues in
the ﬁeld are to understand how neurotoxic-
ity is induced by the prion agent and why it
is not toxic to cells of the immune system.
Another emerging aim is to understand prion
conversion mechanisms and how strain infor-
mation is maintained and transmitted. What
are the mechanisms that deﬁne the tropisms of
prion strains? What is the physiological func-
tion of PrPC? And ﬁnally, the holy grail of all
questions in the prion ﬁeld, what is the ex-
act nature of the prion agent? The ability to
answer these questions in the future will rely
mainly on the quality of the tools and tech-
nologies available to the prion ﬁeld. As the
last years have shown, prionology, a ﬁeld of
interdisciplinary research attracting scientists
from many different ﬁelds, will move ahead to
resolve some of the most important questions
of the prion riddle.
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